Alopecia areata is an autoimmune disorder that causes sudden hair loss on the scalp and other areas of the body. According to Kenia Lepe et al., 2024, it accounts for approximately 2% of the lifetime risk in the general population, with a prevalence of around 1 in 1,000. The alopecia areata pipeline analysis by Expert Market Research highlights the rising development of targeted immunotherapies and JAK inhibitors. With growing focus on personalized treatments, increased clinical trials, and rising awareness, the market for alopecia areata therapeutic products is expected to witness steady growth in the coming years.
Major companies involved in the alopecia areata pipeline analysis include Pfizer, AbbVie, and others.
Leading drugs currently in the pipeline include DR-01, VIS171, and others.
The growth in the alopecia areata pipeline is driven by rising clinical trials for JAK inhibitors, increased FDA fast-track designations, and growing investment in targeted biologics development.
The Alopecia Areata Pipeline Analysis Report by Expert Market Research gives comprehensive insights into alopecia areata therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for alopecia areata. The alopecia areata report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The alopecia areata pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with alopecia areata treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to alopecia areata.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Alopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles, leading to patchy or complete hair loss on the scalp, face, or body. It can begin suddenly and affect people of all ages, with onset often occurring in childhood or early adulthood. The exact cause remains unknown, but genetic and environmental factors may contribute.
Alopecia areata treatment typically involves corticosteroids, topical immunotherapy, or JAK inhibitors to suppress immune response and promote hair regrowth. Treatment choice depends on severity, patient age, and affected areas. In June 2023, Pfizer’s LITFULO™ (ritlecitinib) received FDA approval as the first once-daily oral treatment for adolescents and adults with severe alopecia areata, demonstrating significant hair regrowth in the ALLEGRO Phase 2b/3 trial.
According to Kenia Lepe et al., 2024, alopecia areata has a lifetime risk of approximately 2%, with a prevalence of about 1 in 1,000 individuals. The condition affects both children and adults, with the mean age of onset being 32 years in males and 36 years in females. The incidence is higher among Asian, Black, and Hispanic populations. It is commonly associated with autoimmune and dermatologic disorders such as vitiligo, psoriasis, and thyroid disease.
This section of the report covers the analysis of alopecia areata drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, at 33%, covers a major share of the total alopecia areata clinical trials. This reflects strong mid-stage clinical activity in alopecia areata drug pipeline. Phase III accounts for nearly 28%, showing promising late-stage advancements. Phase I follows with 16%. This balanced progression signals robust innovation and growth potential in the alopecia areata treatment landscape.
The drug molecule categories covered under the alopecia areata pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies. The alopecia areata report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for alopecia areata.
Janus kinase (JAK) inhibitors are gaining prominence in the treatment pipeline for alopecia areata. For instance, upadacitinib, an oral selective JAK inhibitor, is currently being evaluated in a Phase 3 clinical trial sponsored by AbbVie. The study aims to determine the safety, efficacy, and tolerability of upadacitinib in adult participants with severe patchy hair loss due to alopecia areata.
The EMR report for the alopecia areata pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed alopecia areata therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in alopecia areata clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for alopecia areata. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of alopecia areata drug candidates.
DR-01, sponsored by Dren Bio, is currently undergoing a Phase 1b clinical study to evaluate its safety, clinical activity, pharmacokinetics, and pharmacodynamics in adults with alopecia areata or vitiligo. This investigational drug is a novel myeloid cell engager designed for deep B-cell depletion, aiming to modulate autoimmune responses and offer therapeutic benefit to treatment-resistant patients.
VIS171, by Otsuka Pharmaceutical Development & Commercialization, Inc., is currently being evaluated in a Phase 1 open-label trial. The study is assessing the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous VIS171 in participants with autoimmune diseases, including alopecia areata. VIS171 is a novel agent designed to promote regulatory T cell (Treg) expansion to modulate immune dysfunction.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Alopecia Areata Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for alopecia areata. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into alopecia areata collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share